Presentation is loading. Please wait.

Presentation is loading. Please wait.

Toxicity spectra and rankings in the subgroup analysis based on each specific grade 1-5 adverse event and cancer type. Toxicity spectra and rankings in.

Published byÅshild Holmen Modified over 6 years ago

Similar presentations

Presentation on theme: "Toxicity spectra and rankings in the subgroup analysis based on each specific grade 1-5 adverse event and cancer type. Toxicity spectra and rankings in."— Presentation transcript:

1 Toxicity spectra and rankings in the subgroup analysis based on each specific grade 1-5 adverse event and cancer type. Toxicity spectra and rankings in the subgroup analysis based on each specific grade 1-5 adverse event and cancer type. Immune checkpoint inhibitor (ICI) drugs are shown with a dark background. The number in each parenthesis represents the probability of risk to rank; values with the same rank are underlined. Cheng Xu et al. BMJ 2018;363:bmj.k4226 ©2018 by British Medical Journal Publishing Group

Download ppt "Toxicity spectra and rankings in the subgroup analysis based on each specific grade 1-5 adverse event and cancer type. Toxicity spectra and rankings in."

Similar presentations

Frequency of the different drug-eluting stent (DES) used over time (2008–2014) according to active drug component and carrier material (groups >1% only).

Frequency of the different drug-eluting stent (DES) used over time (2008–2014) according to active drug component and carrier material (groups >1% only).
Number of local authorities (LAs) commissioning each service directly or indirectly (n=148) (*Flu vaccination data excludes the service commissioned across.

Number of local authorities (LAs) commissioning each service directly or indirectly (n=148) (*Flu vaccination data excludes the service commissioned across.
Persistence of first tumour necrosis factor alpha inhibitor (TNFi) by TNFi Kaplan-Meier plot of time (years) to discontinuation of treatment by TNFi. (A)

Persistence of first tumour necrosis factor alpha inhibitor (TNFi) by TNFi Kaplan-Meier plot of time (years) to discontinuation of treatment by TNFi. (A)
Mean expense per year on courses and conferences that trainees have not been reimbursed. Mean expense per year on courses and conferences that trainees.

Mean expense per year on courses and conferences that trainees have not been reimbursed. Mean expense per year on courses and conferences that trainees.
Daily contribution (%) of sodium and potassium from major food groups among participants aged 8–12 years (n=517), which includes major food groups provided.

Daily contribution (%) of sodium and potassium from major food groups among participants aged 8–12 years (n=517), which includes major food groups provided.
The core pillars and thematic hallmarks of anti-tumour immunity governing response to immune checkpoint blockade Figure 2 from Cogdill et al. British.

The core pillars and thematic hallmarks of anti-tumour immunity governing response to immune checkpoint blockade Figure 2 from Cogdill et al. British.
Defining study follow-up periods—index date (entry into cohort) and breaks in MSP registration. †End of follow-up due to earliest of: active TB diagnosis,

Defining study follow-up periods—index date (entry into cohort) and breaks in MSP registration. †End of follow-up due to earliest of: active TB diagnosis,
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Total funding for cerebral palsy research by National Health and Medical Research Council (NHMRC, Australia), Cerebral Palsy Alliance Research Foundation.

Total funding for cerebral palsy research by National Health and Medical Research Council (NHMRC, Australia), Cerebral Palsy Alliance Research Foundation.
Incidence trends for each human papillomavirus-related cancer-type among women in Norway 1953–2015. Incidence trends for each human papillomavirus-related.

Incidence trends for each human papillomavirus-related cancer-type among women in Norway 1953–2015. Incidence trends for each human papillomavirus-related.
Scatter graph showing total work time equivalent of all specialist palliative care practitioners commissioned by the Clinical Commissioning Group (CCG)

Scatter graph showing total work time equivalent of all specialist palliative care practitioners commissioned by the Clinical Commissioning Group (CCG)
Scatter graph showing the total number of specialist palliative care beds commissioned compared with the estimated number of people with palliative care.

Scatter graph showing the total number of specialist palliative care beds commissioned compared with the estimated number of people with palliative care.
Estimated probability of successful quitting (quit attempt of longer than 1 year) by quit attempt number in the Ontario Tobacco Survey. Estimated probability.

Estimated probability of successful quitting (quit attempt of longer than 1 year) by quit attempt number in the Ontario Tobacco Survey. Estimated probability.
Differences in life expectancy by SES, sex and remoteness, NSW, 2001 and 2012. Differences in life expectancy by SES, sex and remoteness, NSW, 2001 and.

Differences in life expectancy by SES, sex and remoteness, NSW, 2001 and Differences in life expectancy by SES, sex and remoteness, NSW, 2001 and.
A schematic representation of the possible pairwise comparisons of adherence and persistence between different medication classes. A schematic representation.

A schematic representation of the possible pairwise comparisons of adherence and persistence between different medication classes. A schematic representation.
Masashi Maeda et al. Heart Asia 2013;5:7-14

Masashi Maeda et al. Heart Asia 2013;5:7-14
Transdomain Model of Health.

Transdomain Model of Health.
Mean concentrations (mM) of PG1+2, PG3 and PG4+5 in patients with or without MTX-related toxicity at baseline, week 4 and week 24/26 in (A) CONCERTO and.

Mean concentrations (mM) of PG1+2, PG3 and PG4+5 in patients with or without MTX-related toxicity at baseline, week 4 and week 24/26 in (A) CONCERTO and.
The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.
1-year and 5-year survival rates by cancer type, stage and group, England, up to 2011–2015. 1-year and 5-year survival rates by cancer type, stage and.

1-year and 5-year survival rates by cancer type, stage and group, England, up to 2011– year and 5-year survival rates by cancer type, stage and.

Similar presentations

Ads by Google